Ignite Creation Date:
2024-05-05 @ 4:48 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00312650
Status:
TERMINATED
Last Update Posted:
2015-01-12
First Post:
2006-04-06
Brief Title:
Doxil and Gemcitabine in Recurrent Ovarian Cancer
Sponsor:
Women and Infants Hospital of Rhode Island
Organization:
Women and Infants Hospital of Rhode Island
Study Overview
Official Title:
A Phase II Study of Every 2 Week Doxil and Gemcitabine in Recurrent Ovarian Cancer
Status:
TERMINATED
Status Verified Date:
2015-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Standard treatment for recurrent ovarian cancer is chemotherapy with one or more drugs One of these drugs Doxil can cause skin toxicity at the standard dosages This study investigates using a lower dose given more frequently in combination with a second drug Gemcitabine
Detailed Description:
This study will evaluate the toxicities of Doxil and Gemcitabine given on an every two week basis Our hypothesis is that toxicity will be less than that with standard dosing without any negative effect on survival Patients will also be evaluated with CT scans every 3 months Toxicity will be assessed with every cycle of treatment Treatment will continue until toxicity or signs of progression
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None